<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8269">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01957904</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-015</org_study_id>
    <nct_id>NCT01957904</nct_id>
  </id_info>
  <brief_title>ArterX Safety and Efficacy Study for Cardiac Indications</brief_title>
  <official_title>Prospective, Multi-Center, Open-Label, Post-Market ArterX® Safety and Efficacy Study Protocol for Cardiac Indications</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tenaxis Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tenaxis Medical, Inc.</source>
  <oversight_info>
    <authority>Germany: Bundesministerium für Gesundheit</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to confirm the acute safety and performance of the ArterX® Surgical
      Sealant as a hemostatic agent.  The study will collect data in support of publications and
      future product labeling revisions, to provide additional clinical information on use and
      further details regarding product safety.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with immediate sealing of suture/staple line</measure>
    <time_frame>during surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immediate sealing of the suture/staple line at point of use upon release of the clamps, as evidenced by an absence of clinically significant bleeding  as determined by physician investigator in procedures completed using the ArterX device.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>ArterX Surgical Sealant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ArterX Surgical Sealant</intervention_name>
    <arm_group_label>ArterX Surgical Sealant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        &gt;18 years of age, Male or female If female, subject is post-menopausal, has no child
        bearing potential or has a negative serum or urine pregnancy test within 7 days of the
        index procedure and is practicing abstinence or a highly effective method of contraception
        for the duration of the study.

        The subject or guardian must provide written Informed Consent using a form that is
        reviewed and approved by the Ethics Committee.

        The subject is willing and able to be contacted for 3 months follow-up and attend
        follow-up visits as needed per protocol.

        The subject is determined by the surgeon to be at risk for poor hemostasis.

        Exclusion Criteria:

        Subject undergoing emergency surgery. Subject undergoing minimally invasive surgery.
        Subject has clinically significant medical, psychiatric, or cognitive illness or
        drug/alcohol abuse that in the opinion of the investigator would affect the subject's
        safety or compliance with study assessments or follow-up.

        Subject has immune system disorders/immunodeficiency or immunosuppression. Subject has
        participated in another clinical study within 30 days prior to surgery or has received an
        investigational drug or device within the past 30 days.

        Subject is pregnant, may become pregnant or is currently breast feeding

        -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Krankenhaus Der Barmherzigen Bruder</name>
      <address>
        <city>Trier</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ArterX, surgical sealant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
